ASH 2018: New data presented on synergistic action of LIMK inhibitors with BCR-ABL TKIs

During the 60th American Society of Hematology Congress held in San Diego, Pr Thorsten Braun will present the work performed by the Leukemia Translational Laboratory at Hopital Saint Louis, Paris, on selective LIM Kinase 1/2 inhibitors for combination treatment of BCR-ABL1 Acute Lymphoblastic Leukemia.

This new data, to be presented on December 2 at 6 PM, includes positive results from in vitro experiments and in vivo models, obtained when combining administration of CEL_Amide with BCR-ABL1 Tyrosine Kinase Inhibitors including nilotinib.

It reinforces the rationale for looking into LIM Kinase inhibition as synergistic therapeutic agents with widely used Tyrosine Kinase Inhibitors, located upstream of the Rho-GTPase pathway.

The abstract of the presentation can be consulted online here: ASH 2018 Presentation.

CELLIPSE is developing selective and highly potent LIM Kinase small molecule inhibitors to bring new targeted therapies against cancer indications with poor overall prognosis and high medical need such as Acute Myeloïd Leukemia (AML), Acute Lymphoblastic Leukemia (ALL) and other Myeloproliferative Neoplasms.

CEL_Amide is CELLIPSE’s Lead Candidate for developing and introducing in the clinic first-in-class LIM Kinase inhibitors.